Cassava Sciences Inc. (SAVA)
NASDAQ (CM) 
SAVA LAWSUIT ALERT: Levi & Korsinsky Notifies Cassava Sciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, NY / ACCESSWIRE / December 13, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
SAVA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cassava Sciences, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK, NY / ACCESSWIRE / December 13, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period").
Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - SAVA
NEW YORK, NY / ACCESSWIRE / December 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava Sciences, Inc. ("Cassava Sciences, Inc.") (NASDAQ:SAVA) concerning possible violations of federal securities laws. On November 25, 2024, Cassava "today announced that the topline results from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate AD [Alzheimer's Disease] did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CassavaSciences, Inc. - SAVA
NEW YORK, NY / ACCESSWIRE / December 11, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ:SAVA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Cassava Sciences, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - SAVA
NEW YORK, NY / ACCESSWIRE / December 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava Sciences, Inc. ("Cassava Sciences, Inc.") (NASDAQ:SAVA) concerning possible violations of federal securities laws. On November 25, 2024, Cassava "today announced that the topline results from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate AD [Alzheimer's Disease] did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints.
Bronstein, Gewirtz & Grossman, LLC Encourages Cassava Sciences, Inc. (SAVA) Shareholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESSWIRE / December 10, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA). Investors who purchased Cassava securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAVA.
SAVA STOCK ALERT: Levi & Korsinsky Notifies Cassava Sciences, Inc. Investors of an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / December 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava Sciences, Inc. ("Cassava Sciences, Inc.") (NASDAQ:SAVA) concerning possible violations of federal securities laws. On November 25, 2024, Cassava "today announced that the topline results from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate AD [Alzheimer's Disease] did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Cassava Sciences, Inc. (SAVA) And Encourages Shareholders to Connect
NEW YORK CITY, NY / ACCESSWIRE / December 9, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA). Investors who purchased Cassava securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAVA.
Cassava Sciences, Inc. (SAVA) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
NEW YORK, NY / ACCESSWIRE / December 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava Sciences, Inc. ("Cassava Sciences, Inc.") (NASDAQ:SAVA) concerning possible violations of federal securities laws. On November 25, 2024, Cassava "today announced that the topline results from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate AD [Alzheimer's Disease] did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Cassava Sciences, Inc. (SAVA) And Encourages Shareholders to Reach Out
NEW YORK CITY, NY / ACCESSWIRE / December 8, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA). Investors who purchased Cassava securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAVA.
Did Cassava Sciences, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - SAVA
NEW YORK, NY / ACCESSWIRE / December 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava Sciences, Inc. ("Cassava Sciences, Inc.") (NASDAQ:SAVA) concerning possible violations of federal securities laws. On November 25, 2024, Cassava "today announced that the topline results from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate AD [Alzheimer's Disease] did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cassava Sciences, Inc. (SAVA) and Encourages Shareholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / December 6, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA). Investors who purchased Cassava securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAVA.
